Literature DB >> 18774443

Adverse events from the treatment of Parkinson's disease.

Kelvin L Chou1.   

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized clinically by resting tremor, rigidity, bradykinesia, and postural instability. Effective medications exist to treat these motor symptoms but can be associated with adverse effects. When severe, these adverse effects can interfere with a patient's quality of life. In this article, the most common adverse events from PD treatment are discussed, including nausea, dyskinesias, somnolence, compulsive behaviors, psychosis, and peripheral edema. Additionally, melanoma and weight loss, two conditions that have been variably linked to PD treatment, are reviewed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774443     DOI: 10.1016/j.ncl.2008.05.003

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  9 in total

1.  Case files of the program in medical toxicology at brown university: amantadine withdrawal and the neuroleptic malignant syndrome.

Authors:  Eric Brantley; Jamieson Cohn; Kavita Babu
Journal:  J Med Toxicol       Date:  2009-06

2.  Preladenant, a selective adenosine A₂A receptor antagonist, is not associated with QT/QTc prolongation.

Authors:  Z Wang; F Xuan; W H Lin; M D Troyer; A Tendolkar; D L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2013-07-16       Impact factor: 2.953

Review 3.  Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease.

Authors:  Lindy D Wood
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

4.  Discovery of Potent and Selective A2A Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression.

Authors:  Sujay Basu; Dinesh A Barawkar; Vidya Ramdas; Minakshi Naykodi; Yogesh D Shejul; Meena Patel; Sachin Thorat; Anil Panmand; K Kashinath; Rajesh Bonagiri; Vandna Prasad; Ganesh Bhat; Azfar Quraishi; Sumit Chaudhary; Amol Magdum; Ashwinkumar V Meru; Indraneel Ghosh; Ravi K Bhamidipati; Amol A Raje; Vamsi L M Madgula; Siddhartha De; Sreekanth R Rouduri; Venkata P Palle; Anita Chugh; Narayanan Hariharan; Kasim A Mookhtiar
Journal:  ACS Med Chem Lett       Date:  2017-07-05       Impact factor: 4.345

Review 5.  How Wearable Sensors Can Support Parkinson's Disease Diagnosis and Treatment: A Systematic Review.

Authors:  Erika Rovini; Carlo Maremmani; Filippo Cavallo
Journal:  Front Neurosci       Date:  2017-10-06       Impact factor: 4.677

6.  Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials.

Authors:  Robert A Hauser; Nobutaka Hattori; Hubert Fernandez; Stuart H Isaacson; Hideki Mochizuki; Olivier Rascol; Fabrizio Stocchi; June Li; Akihisa Mori; Yu Nakajima; Robert Ristuccia; Peter LeWitt
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

7.  Serotonin-Related Functional Genetic Variants Affect the Occurrence of Psychiatric and Motor Adverse Events of Dopaminergic Treatment in Parkinson's Disease: A Retrospective Cohort Study.

Authors:  Sara Redenšek; Tanja Blagus; Maja Trošt; Vita Dolžan
Journal:  J Pers Med       Date:  2022-02-11

Review 8.  Istradefylline for OFF Episodes in Parkinson's Disease: A US Perspective of Common Clinical Scenarios.

Authors:  Stuart H Isaacson; Sagari Betté; Rajesh Pahwa
Journal:  Degener Neurol Neuromuscul Dis       Date:  2022-07-23

9.  Effectiveness of therapeutic massage for improving motor symptoms in Parkinson's disease: A systematic review and meta-analysis.

Authors:  Zhiran Kang; Hua Xing; Qiang Lin; Fanchao Meng; Li Gong
Journal:  Front Neurol       Date:  2022-09-05       Impact factor: 4.086

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.